...ast Whole Genome ChIP-on-chip Microarray is specif... cerevisiae) DNA binding proteins by pairing chrom...icroarrays. This set delivers robust hybridization...ng events and fewer false positives. In addition, ...
... pombe Whole Genome ChIP-on-chip Microarray is spe...(S. pombe) DNA binding proteins by pairing chromat...roarrays. This set delivers robust hybridization a... events and fewer false positives. In addition, Ag...
...it is designed for easy transformation of the budd...or successful transformation simply by mixing a pl... cells. No complicated steps, such as centrifugati...cularly well suited for high-throughput transforma...
...effort to help promote genomics-based research wit...ylococcus aureus ORFmer set that contains PCR prim...he COL strain1. In addition, primer pairs are incl...u50 and N315 strains of S. aureus. The ORFmer set ...
Biology Products:..., the causative agent of anthrax, has been cleared...nistration (FDA). The test, known as the Gamma Pha...rmy Medical Research Institute of Infectious Disea...ability when used with clinical specimens. The ori...loped by the Centers for Disease Control and Preve...
... at Cornell University has received a grant to hel...aize (corn). , The project not only will allow re... function of single genes, one at a time, but also... gene. The seeds will be made widely available to ...ead to plants with tailor-made properties, such as...
...ing that the ability to taste bitter compounds has...Animals rely on chemical perception, including the... the harmful compounds found in nature. It is wide...y have reduced the importance of such chemical per...mans. , In new work, researchers including Nicole...
Other Biology News:'Mad cow' proteins successfully detected in blood 2'Mad cow' proteins successfully detected in blood 3Researcher gets NSF grant to create mutant maize lines 2Researcher gets NSF grant to create mutant maize lines 3(Date:11/20/2009)... Karolinska Development AB today,an...s entered into a,co-investment agreement with the ... Karolinska Development and used to invest in the ...and medical technology companies. EIF,has agreed t...he agreement,represents EIF,s largest single inves...
(Date:11/20/2009)...ecently announced that Dr. Dominique Hebrault will...s Analytical Technology (PAT) in Green Chemistry a..., (PRWEB) November 20, 200...chnology (PAT) in Green Chemistry and Green Engine...echnology (PAT) case studies will be presented on ...
(Date:11/19/2009)...rstCall/ -- Omeros Corporation (Nasdaq: OMER ) to...third quarter ended September 30, 2009. For the th...ed a net loss of $3.9 million, or $1.34 per share,...54 per share, for the same period in 2008. For the... reported a net loss of $15.5 million, or $5.29 pe...
(Date:11/19/2009)...irstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), ann... to its shareholders, discussing the Company,s acq...euticals Holdings, Inc. (CHBP), an integrated bio-...lic of China. The merger gives NeoStem a controlli...Ltd., CHBP,s primary operating subsidiary and a pr...
Breaking Biology Technology:Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 3Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3